A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Registration Number
- NCT02031458
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 667
- Adult participants greater than or equal to 18 years of age
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
- Measurable disease, as defined by RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:
Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1
- Central nervous system (CNS) disease, including treated brain metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted
- Active hepatitis B or hepatitis C
- Human Immunodeficiency virus (HIV) positive
- Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Atezolizumab Atezolizumab -
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Objective Response (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 as Assessed by Independent Review Facility (IRF) Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) ORR was the percentage of participants whose confirmed best overall response was either a Partial Response (PR) or a Complete Response (CR) based upon the IRF assessment per RECIST v1.1. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm); PR:greater than (\>) or equal to (=) 30 percent (%) decrease from baseline in sum of diameters of target lesions, non-progressive disease (PD) non-target lesions and no new lesions. Results were reported by line of therapy and programmed death-ligand 1 (PD-L1) Expression Subgroup (tumor cell \[TC\]3 \[TC3\] or tumor-infiltrating immune cell \[IC\] 3 \[IC3\], TC3 or IC2/3, TC2/3 or IC2/3).
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by IRF Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PFS is the interval between the first dose of atezolizumab and date of disease progression or death due to any cause, whichever occurred first as measured by RECIST v1.1. PD is defined as one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions. PFS was assessed by Kaplan-Meier estimates.
PFS: Percentage of Participants Alive and Progression Free at 6 Months Month 6 PD is defined as one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions.
Percentage of Participants With Event (Disease Progression or Death) as Assessed by IRF Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PD was defined as one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5 mm), appearance of new lesions, and/or unequivocal progression of non-target lesions.
Percentage of Participants Achieving Objective Response Per RECIST v1.1 as Assessed by the Investigator (INV) Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) ORR was the percentage of participants whose confirmed best overall response was either a PR or a CR based upon the Investigator assessment per RECIST v1.1. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10mm; PR: \> or = 30 % decrease from baseline in sum of diameters of target lesions, non-PD non-target lesions and no new lesions. Results were reported by line of therapy (reporting arms) and PD-L1 Expression Subgroup (TC3 or IC3, TC3 or IC2/3, TC2/3 or IC2/3).
DOR as Assessed by INV Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) DOR is interval between date of the first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and first date that PD or death is documented, whichever occurs first as measured by RECIST v1.1. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10mm; PR: \> or = 30 % decrease from baseline in sum of diameters of target lesions, non-PD non-target lesions and no new lesions; PD: one or more of the following: at least 20% increase from nadir in sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions. DOR was assessed by Kaplan-Meier estimates. Results were reported by line of therapy (reporting arms) and PD-L1 Expression Subgroup (TC3 or IC3, TC3 or IC2/3, TC2/3 or IC2/3).
DOR as Assessed by INV Per Modified RECIST Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) DOR is the interval between the date of the first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and the first date that PD or death is documented, whichever occurs first as measured by modified RECIST. CR: disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10mm; PR: at least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR; PD: one or more of the following: at least 20% increase from nadir in the sum of diameters of existing and/or new target lesions (with an absolute increase of at least 5mm). DOR was assessed by Kaplan-Meier estimates. Results were reported by line of therapy (reporting arms) and PD-L1 Expression Subgroup (TC3 or IC3, TC3 or IC2/3, TC2/3 or IC2/3).
Percentage of Participants Achieving Objective Response Per Modified RECIST as Assessed by the INV Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) ORR was the percentage of participants whose confirmed best overall response was either a PR or a CR based upon the Investigator assessment per modified RECIST. CR: disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10mm; PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. Results were reported by line of therapy (reporting arms) and PD-L1 Expression Subgroup (TC3 or IC3, TC3 or IC2/3, TC2/3 or IC2/3).
Percentage of Participants Without an Event (Death) at 6 Months Month 6 Percentage of Participants Without an Event (Death) at 12 Months Month 12 PFS as Assessed by INV Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PFS is the interval between the first dose of atezolizumab and date of disease progression or death due to any cause, whichever occurred first as measured by RECIST v1.1. PD: one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions. PFS was assessed by Kaplan-Meier estimates.
PFS as Assessed by INV Per Modified RECIST Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PFS is the interval between the first dose of atezolizumab and date of disease progression or death due to any cause, whichever occurred first as measured by modified RECIST. PD: at least 20% increase from nadir in the sum of diameters of new and/or existing target lesions (with an absolute increase of at least 5mm). PFS was assessed by Kaplan-Meier estimates.
Time in Response (TIR) as Assessed by INV Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) TIR is interval between date of first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and first date that PD or death is documented, whichever occurs first as measured by RECIST v1.1. For responders, TIR was the same as DOR; for non-responders, TIR was considered as an event and defined as the date of first treatment plus one day. TIR was assessed by Kaplan-Meier estimates.
TIR as Assessed by INV Per Modified RECIST Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) TIR is interval between date of first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and first date that PD or death is documented, whichever occurs first as measured by modified RECIST. For responders, TIR was the same as DOR; for non-responders, TIR was considered as an event and defined as the date of first treatment plus one day. TIR was assessed by Kaplan-Meier estimates.
Percentage of Participants With Positive Anti-Therapeutic Antibody (Anti-Atezolizumab Antibody) Status Baseline, post-baseline (up to 16 months) Anti-therapeutic antibodies is a measurement to explore the potential relationship of immunogenicity response with pharmacokinetics, safety and efficacy.
Percentage of Participants With Event (Disease Progression or Death) as Assessed by INV Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PD was defined as one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5 mm), appearance of new lesions, and/or unequivocal progression of non-target lesions.
Duration of Response (DOR) Assessed by IRF Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) DOR is interval between date of first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and the first date that PD or death is documented, whichever occurs first as measured by RECIST v1.1. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10mm; PR: \> or = 30 % decrease from baseline in sum of diameters of target lesions, non-PD non-target lesions and no new lesions; PD: one or more of the following: at least 20% increase from nadir in sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions. DOR was assessed by Kaplan-Meier estimates. Results were reported by line of therapy (reporting arms) and PD-L1 Expression Subgroup (TC3 or IC3, TC3 or IC2/3, TC2/3 or IC2/3).
Overall Survival : Median Time to Event (Death) Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) Overall survival is measured as interval between the first dose of atezolizumab and date of death from any cause.
Overall Survival : Percentage of Participants Without Event (Death) Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) Atezolizumab Serum Concentrations Pre-dose (hour 0) and 0.5 hours post dose on Cycle 1 Day 1 (Cycle length = 21days), Cycle 1 Days 2, 4, 8, 15, and 21, Cycle 2 Day 21, Cycle 3 Day 21, Cycle 7 Day 21 Serum concentrations were determined for all participants after administration of atezolizumab up to Cycle 8. Time (T) = time from first dose in days.
Percentage of Participants With Event (Disease Progression or Death) as Assessed by INV Per Modified RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) PD was defined as at least 20% increase from nadir in the sum of diameters of new and/or existing target lesions (with an absolute increase of at least 5 mm).
PFS: Percentage of Participants Alive and Progression Free at 12 Months Month 12 PD is defined as one or more of the following: at least 20% increase from nadir in the sum of diameters of target lesions (with an absolute increase of at least 5mm), appearance of new lesions, and/or unequivocal progression of non-target lesions.
TIR as Assessed by IRF Per RECIST v1.1 Screening, Every 6 weeks (± 3 days) for 12 months following Cycle 1, Day 1 and every 9 weeks (± 1 week) thereafter until disease progression, intolerable toxicity or death until data cut-off on 28 May 2015 (Up to 16 months) TIR is interval between date of first occurrence of a CR or PR that is subsequently confirmed (whichever status is recorded first) and first date that PD or death is documented, whichever occurs first as measured by RECIST v1.1. For responders, TIR was the same as DOR; for non-responders, TIR was considered as an event and defined as the date of first treatment plus one day. TIR was assessed by Kaplan-Meier estimates.
Trial Locations
- Locations (110)
Angeles Clinic & Rsch Inst
🇺🇸Los Angeles, California, United States
Emory Uni - Winship Cancer Center; Hematology/Oncology
🇺🇸Atlanta, Georgia, United States
The Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Lakeridge Health Oshawa; Oncology
🇨🇦Oshawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
Centre Leon Berard; Departement Oncologie Medicale
🇫🇷Lyon, France
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
City of Hope National Medical Group
🇺🇸South Pasadena, California, United States
Stanford Cancer Center
🇺🇸Stanford, California, United States
University of Colorado Health Science Center; Biomedical Research Bldg. Room 511
🇺🇸Aurora, Colorado, United States
Georgetown University Medical Center Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Florida Hospital Cancer Inst
🇺🇸Orlando, Florida, United States
Northwest Georgia Oncology Centers PC - Marietta
🇺🇸Marietta, Georgia, United States
Northwestern University; Robert H. Lurie Comp Can Ctr
🇺🇸Chicago, Illinois, United States
University Of Chicago Medical Center; Section Of Hematology/Oncology
🇺🇸Chicago, Illinois, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Monter Cancer Center
🇺🇸Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Oncology Hematology Care Inc
🇺🇸Cincinnati, Ohio, United States
Ohio State University; B406 Starling-Loving Hall
🇺🇸Columbus, Ohio, United States
Penn State Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
Fox Chase Cancer Center; Hematology/Oncology
🇺🇸Philadelphia, Pennsylvania, United States
University of Virginia; Office of Sponsored Programs
🇺🇸Charlottesville, Virginia, United States
University of Washington Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Royal North Shore Hospital; Oncology
🇦🇺St. Leonards, New South Wales, Australia
Peter Maccallum Cancer Institute; Medical Oncology
🇦🇺Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital; Medical Oncology
🇦🇺Nedlands, Western Australia, Australia
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Sint Augustinus Wilrijk
🇧🇪Wilrijk, Belgium
University Clinical Center Sarajevo;Clinic for Pulmonary disease
🇧🇦Sarajevo, Bosnia and Herzegovina
BCCA-Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
Hopital Augustin Morvan; Oncologie Thoracique
🇫🇷Brest, France
Hopital Arnaud De Villeneuve; Maladies Respiratoires
🇫🇷Montpellier, France
Centre René Gauducheau - cancer Nantes - Atlantique; Service Oncologie Médicale
🇫🇷Nantes, France
Nouvel Hopital Civil; Pneumologie
🇫🇷Strasbourg, France
Research institute for Clinical Medicine
🇬🇪Tbilisi, Georgia
Institut Gustave Roussy; Departement Oncologie Medicale
🇫🇷Villejuif, France
Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
🇩🇪Essen, Germany
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
🇮🇹Meldola, Emilia-Romagna, Italy
Yokohama Municipal Citizen'S Hospital; Respiratory Medicine
🇯🇵Kanagawa, Japan
Kitasato University Hospital; Respiratory Medicine
🇯🇵Kanagawa, Japan
Osaka Habikino Medical Center
🇯🇵Osaka, Japan
National Cancer Center Hospital; Thoracic Medical Oncology
🇯🇵Tokyo, Japan
Toranomon Hospital; Respiratory Medicine
🇯🇵Tokyo, Japan
Academ Ziekenhuis Groningen; Medical Oncology
🇳🇱Groningen, Netherlands
National University Hospital; National University Cancer Institute, Singapore (NCIS)
🇸🇬Singapore, Singapore
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Ankara, Turkey
Ankara Ataturk Chest Diseases Training and Research Hospital
🇹🇷Ankara, Turkey
Barts & London School of Med; Medical Oncology
🇬🇧London, United Kingdom
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Royal Marsden NHS Foundation Trust
🇬🇧Sutton, United Kingdom
Complex Oncology Center (COC)-Plovidiv
🇧🇬Plovdiv, Bulgaria
HonorHealth Research Institute - Bisgrove
🇺🇸Scottsdale, Arizona, United States
Hematology Oncology Associates of the Treasure Coast
🇺🇸Port Saint Lucie, Florida, United States
Yale Cancer Center; Medical Oncology
🇺🇸New Haven, Connecticut, United States
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Florida Cancer Specialists; SCRI
🇺🇸Fort Myers, Florida, United States
Florida Cancer Specialists.
🇺🇸Saint Petersburg, Florida, United States
Beth Israel Deaconess Med Ctr; Hem/Onc
🇺🇸Boston, Massachusetts, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Uni of Maryland; Greenebaum Cancer Center
🇺🇸Baltimore, Maryland, United States
Tennessee Oncology PLLC - Nashville (20th Ave)
🇺🇸Nashville, Tennessee, United States
GHdC Site Saint-Joseph
🇧🇪Charleroi, Belgium
Hopital Cote De Nacre; Pneumologie
🇫🇷Caen, France
LungenClinic Großhansdorf GmbH
🇩🇪Großhansdorf, Germany
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Huntsman Cancer Institute; University of Utah
🇺🇸Salt Lake City, Utah, United States
Klinikum Nuernberg Nord; Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin
🇩🇪Nürnberg, Germany
Queen Elizabeth Hospital; Clinical Oncology
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital; Dept. of Clinical Oncology
🇭🇰Hong Kong, Hong Kong
Austin Health
🇦🇺Heidelberg, Victoria, Australia
Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine
🇯🇵Kanagawa, Japan
Sendai Kousei Hospital; Pulmonary Medicine
🇯🇵Miyagi, Japan
University of Wisconsin
🇺🇸Madison, Wisconsin, United States
Princess AleXandra Hospital; Department of Medical Oncology
🇦🇺Woolloongabba, Queensland, Australia
University Clinical Centre of the Republic of Srpska
🇧🇦Banja Luka, Bosnia and Herzegovina
University Clinical Center Sarajevo;Institute of oncology
🇧🇦Sarajevo, Bosnia and Herzegovina
Specialized Hospital for Active Treatment of Oncology
🇧🇬Sofia, Bulgaria
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
🇮🇹Milano, Lombardia, Italy
The Ottawa Hospital Cancer Centre; Oncology
🇨🇦Ottawa, Ontario, Canada
Cancer Research Centre
🇬🇪Tbilisi, Georgia
MediClab Georgia
🇬🇪Tbilisi, Georgia
Prince of Wales Hosp; Dept. Of Clinical Onc
🇭🇰Shatin, Hong Kong
CHU Limoges - Dupuytren; Oncologie Thoracique Cutanee
🇫🇷Limoges, France
Chemotherapy and Immunotherapy Clinic Medulla
🇬🇪Tbilisi, Georgia
Amphia Ziekenhuis; Afdeling Longziekten
🇳🇱Breda, Netherlands
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
🇨🇦Toronto, Ontario, Canada
CHUV; Departement d'Oncologie
🇨🇭Lausanne, Switzerland
Pius-Hospital; Klinik fuer Haematologie und Onkologie
🇩🇪Oldenburg, Germany
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
🇩🇪Villingen-Schwenningen, Germany
Kyoto University Hospital, Respiratory Medicine
🇯🇵Kyoto, Japan
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
🇨🇭Zürich, Switzerland
Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico
🇮🇹Orbassano, Piemonte, Italy
National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine
🇯🇵Fukuoka, Japan
Kansai Medical university Hospital; Thoracic Oncology
🇯🇵Osaka, Japan
National Cancer Centre; Medical Oncology
🇸🇬Singapore, Singapore
Universitaetsspital Basel; Onkologie
🇨🇭Basel, Switzerland
Osaka International Cancer Institute; Thoracic Oncology
🇯🇵Osaka, Japan
Antoni Van Leeuwenhoek Ziekenhuis; Thoracic Oncology
🇳🇱Amsterdam, Netherlands
Ege University School of Medicine; Chest Diseases Department
🇹🇷Izmir, Turkey
Kantonsspital St. Gallen; Onkologie/Hämatologie
🇨🇭St. Gallen, Switzerland
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
🇹🇷Malatya, Turkey
Carolina BioOncology Institute, PLCC
🇺🇸Huntersville, North Carolina, United States
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Barcelona, Spain
ICO Badalona - Hospital Germans Trias i Pujol
🇪🇸Barcelona, Spain
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
🇪🇸Sevilla, Spain